Surgery
The usefulness of full-thickness biopsy during semi-rigid pleuroscopy for differentiating between malignant pleural mesothelioma and non-specific pleurisy
BMC Pulmonary Medicine 2025 December 10 [Link] Takahiro Ueda, Toshiyuki Nakai, Sayaka Tanaka, Hiroaki Nagamine, Atsushi Miyamoto, Misako Nishimura, Yoshiya Matsumoto, Kanako Sato, Kazuhiro Yamada, Tetsuya Watanabe, Kazuhisa Asai, Yuji Matsumoto, Yu Mikami, Tomoya Kawaguchi Abstract Background: Malignant pleural mesothelioma is a rare disease with a poor prognosis; distinguishing it from non-specific pleurisy is essential…
Read MoreCirculating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma
Lung Cancer 2025 December [Link] Evgeniya Sharova, Paola Del Bianco, Loredana Urso, Micol Silic-Benussi, Daniela Scattolin, Donna M D’Agostino, Giulia Pasello, Vincenzo Ciminale Abstract Introduction: Pleural mesothelioma (PM) is an aggressive neoplasm associated with asbestos exposure. Clinical management of PM poses major challenges due to the lack of reliable markers for early diagnosis and prognostic…
Read MoreNeoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review
Translational Lung Cancer Research 2025 October 31 [Link] Illaa Smesseim, Jo Raskin, Jacobus A Burgers Abstract Background: Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The role of surgery in its management remains controversial, with ongoing debate regarding the definition of resectable disease. Neoadjuvant therapy aims to reduce tumor burden. This systematic review…
Read MoreDynamic evolution of NK cells and immune remodeling mediated by CRS + HIPEC: prognostic mechanisms and therapeutic implications for malignant peritoneal mesothelioma
World Journal of Surgical Oncology 2025 November 3 [Link] Yi-Tong Liu, Qi-Di Zhao, Xin-Li Liang, Ru Ma, Yan-Dong Su, Rui Yang, Tian Wei, He-Liang Wu, Yu-Bin Fu, Yu-Run Cui, Yang Yu, Bing Li, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a highly aggressive peritoneal malignancy with a significant recurrence rate following cytoreductive surgery…
Read MorePD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research 2025 September 30 [Link] Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka Abstract Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various…
Read MoreComparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma
Clinical Medicine Insights Oncology 2025 October 17 [Link] Doğan Bayram, Safa Can Efil, Serap Türk, Oğuz Kara, Serhat Sekmek, Şebnem Yücel, Selin Aktürk Esen, Gökhan Uçar, Oznur Bal, Efnan Algin, Doğan Uncu Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare and progressive cancer originating from the mesothelial cells of the peritoneum. In patients with…
Read MorePleurectomy/Decortication Versus Extrapleural Pneumonectomy in Pleural Mesothelioma: A Systematic Review and Meta-Analysis of Survival, Mortality, and Surgical Trends
Journal of Clinical Medicine 2025 August 23 [Link] Margherita Brivio, Matteo Chiari, Claudia Bardoni, Antonio Mazzella, Monica Casiraghi, Lorenzo Spaggiari, Luca Bertolaccini Abstract Background: The optimal surgical approach for malignant pleural mesothelioma (PM) remains a topic of debate. While extrapleural pneumonectomy (EPP) offers radical resection, it is associated with significant morbidity. Pleurectomy/decortication (P/D) is less…
Read MorePerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J Battafarano, Russell K Hales, Joseph Friedberg, Boris Sepesi, Julie S Deutsch, Tricia Cottrell, Janis…
Read MoreEfficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching
International Journal of Cancer 2025 September 2 [Link] Xin-Li Liang, Yan-Dong Su, Yu-Bin Fu, Yang Yu, Xin-Bao Li, Zhong-He Ji, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li Abstract To investigate the efficacy of postoperative immunotherapy in patients with malignant peritoneal mesothelioma (MPM) after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).…
Read MoreEffectiveness of Surgical Treatment on Survival of Patients with Malignant Pleural Mesothelioma
Cancers 2025 July 16 [Link] Renata Báez-Saldaña, María Esther Marmolejo-Torres, Marco Antonio Iñiguez-García, Aída Jiménez-Corona, Juan Alberto Berrios-Mejía Abstract Background: The benefit of surgery for malignant pleural mesothelioma is highly debated, as few robust clinical trials show its effectiveness. Objective: To examine the long-term survival of patients with malignant pleural mesothelioma who underwent surgical treatment…
Read More
Skip to content